Suggested remit - To appraise the clinical and cost effectiveness of atezolizumab with gemcitabine and carboplatin within its marketing authorisation for treating untreated metastatic urothelial bladder cancer.
Status In progress
Process STA 2018
ID number 1206

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
21 November 2019 - 28 November 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 February 2018 In progress, Topic referred 21 April 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance